Vaccines against infectious diseases have been hailed as the greatest achievement in public health over the last century. This competing renewal will investigate a novel adjuvant that elicits cellular immune responses needed for better vaccines. The lack of an appropriate adjuvant is one major barrier to developing a safe and effective vaccine against infections with fungal pathogens, which represents an unmet need in medicine and public health. Despite the rising rates of severe fungal infections, no vaccines against fungi are commercially available. While current vaccines against infectious diseases preferentially induce production of antibodies, their contribution to host defense against fungi is limited. Cellular immunity is essential for the resolution of fungal infections. Vaccine-induced resistance against fungi in experimental models requires Th17 and Th1 cells that produce IL-17 and IFN-? and mediate protection in part by recruiting and activating phagocytes to augment killing of fungi. In the last funding cycle, we discovered that fungal recognition by the C-type lectin receptor (CLR) Dectin-2 is required for the differentiation of protective Th17 and Th1 cells against dimorphic fungi. Through biochemical purification and mass spectrophotometry analysis, we identified a novel bona-fide fungal ligand for Dectin-2, the glycoprotein Blastomyces Eng3 (Bl-Eng3). In this application, we propose to characterize and functionally test Bl-Eng3 as an adjuvant for vaccination against fungi. We hypothesize that Bl-Eng3 activates dendritic cells, drives differentiation of antigen (Ag)-specific Th17 and Th1 cells, and thereby promotes protective cellular immunity against fungal infection. We also posit that the protein backbone and glycan modifications account for ligand activity and that Bl-Eng3 will be an effective adjuvant alone or together with other CLR ligands for vaccines against fungi. We provide strong preliminary data to support our hypotheses. Using Dectin-2 reporter cells, we have established an in vitro screening system to dissect the contributions of the protein backbone and its glycosylation to Dectin-2 ligand activity and an in vivo adoptive transfer system to delineate the effects of the ligand adjuvant on the differentiation of nave antigen-specific CD4+ T-cells into protective Th17 and Th1 cells. Our approach offers a powerful complimentary strategy that will identify the ligand moiety of the glycoprotein in aim 1, assess adjuvancy for the maturation and priming of Ag-presenting cells (APCs) and Ag-specific T cells in aim 2, and determine receptor collaboration with other CLRs and protective efficacy in experimental models of pulmonary and systemic fungal infections in aim 3. Our work will provide new insight needed to promote the maturation of APCs and differentiation of protective Th17 and Th1 cells. This knowledge will provide the basis for developing and designing new vaccine strategies against fungi, and other pathogenic microbes that require cellular immunity for host defense.

Public Health Relevance

The number of fungal infections has risen dramatically in the United States over the last 10 years, and is now among the top 10 causes of death, partly because we lack vaccines against fungi. To address this unmet medical need, we are working on vaccine strategies and have discovered a novel adjuvant that we will characterize and functionally test in vaccines against fungi. The knowledge gained will lead to the development of new and better vaccines against microbial pathogens.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI093553-09
Application #
9976397
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Love, Dona
Project Start
2011-05-03
Project End
2021-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
9
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Pediatrics
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Kujoth, Gregory C; Sullivan, Thomas D; Merkhofer, Richard et al. (2018) CRISPR/Cas9-Mediated Gene Disruption Reveals the Importance of Zinc Metabolism for Fitness of the Dimorphic Fungal Pathogen Blastomyces dermatitidis. MBio 9:
Kottom, Theodore J; Hebrink, Deanne M; Jenson, Paige E et al. (2018) Dectin-2 Is a C-Type Lectin Receptor that Recognizes Pneumocystis and Participates in Innate Immune Responses. Am J Respir Cell Mol Biol 58:232-240
Garfoot, Andrew L; Goughenour, Kristie D; Wüthrich, Marcel et al. (2018) O-Mannosylation of Proteins Enables Histoplasma Yeast Survival at Mammalian Body Temperatures. MBio 9:
Hernández-Santos, Nydiaris; Wiesner, Darin L; Fites, J Scott et al. (2018) Lung Epithelial Cells Coordinate Innate Lymphocytes and Immunity against Pulmonary Fungal Infection. Cell Host Microbe 23:511-522.e5
Kalantari, Parisa; Morales, Yoelkys; Miller, Emily A et al. (2018) CD209a Synergizes with Dectin-2 and Mincle to Drive Severe Th17 Cell-Mediated Schistosome Egg-Induced Immunopathology. Cell Rep 22:1288-1300
Wiemann, Philipp; Perevitsky, Adi; Lim, Fang Yun et al. (2017) Aspergillus fumigatus Copper Export Machinery and Reactive Oxygen Intermediate Defense Counter Host Copper-Mediated Oxidative Antimicrobial Offense. Cell Rep 19:1008-1021
Nanjappa, Som Gowda; McDermott, Andrew J; Fites, J Scott et al. (2017) Antifungal Tc17 cells are durable and stable, persisting as long-lasting vaccine memory without plasticity towards IFN? cells. PLoS Pathog 13:e1006356
Walsh, Naomi M; Wuthrich, Marcel; Wang, Huafeng et al. (2017) Characterization of C-type lectins reveals an unexpectedly limited interaction between Cryptococcus neoformans spores and Dectin-1. PLoS One 12:e0173866
Kottom, Theodore J; Hebrink, Deanne M; Jenson, Paige E et al. (2017) The Interaction of Pneumocystis with the C-Type Lectin Receptor Mincle Exerts a Significant Role in Host Defense against Infection. J Immunol 198:3515-3525
Wang, Huafeng; Lee, Taek-Jin; Fites, Scott J et al. (2017) Ligation of Dectin-2 with a novel microbial ligand promotes adjuvant activity for vaccination. PLoS Pathog 13:e1006568

Showing the most recent 10 out of 38 publications